IDEXX Laboratories Expects 2024 Adjusted EPS Of $10.37-$10.53 Versus Prior Guidance Of $10.31-$10.59 And Consensus Of $10.56
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories has narrowed its 2024 adjusted EPS outlook to $10.37-$10.53, maintaining a consistent midpoint compared to prior guidance. This is supported by solid operating margin performance and benefits from lower projected interest expense and effective tax rate.
October 31, 2024 | 10:44 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IDEXX Laboratories has adjusted its 2024 EPS guidance to $10.37-$10.53, maintaining a consistent midpoint. The company expects solid operating margins and benefits from lower interest expenses and tax rates.
IDEXX Laboratories' adjustment of its EPS guidance reflects a stable outlook with a consistent midpoint, indicating no significant change in expected performance. The company's solid operating margins and reduced expenses provide a stable financial foundation, but the guidance is slightly below consensus, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100